Cargando…

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?

Detalles Bibliográficos
Autor principal:	Maher, Toby M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890254/ https://www.ncbi.nlm.nih.gov/pubmed/35580066 http://dx.doi.org/10.1164/rccm.202205-0839ED

Ejemplares similares

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Adult Interstitial Lung Abnormalities: The New Frontier of Pulmonary Fibrosis
por: Luo, FengMing, et al.
Publicado: (2023)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Is pirfenidone ready for use in non-idiopathic pulmonary fibrosis interstitial lung diseases?
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease
por: Harari, Sergio
Publicado: (2018)

Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis
por: Hunninghake, Gary M
Publicado: (2019)

Potential interstitial lung abnormalities on chest X-rays prior to symptoms of idiopathic pulmonary fibrosis
por: Hoffman, T. W., et al.
Publicado: (2022)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Using Data on Survival with Idiopathic Pulmonary Fibrosis to Estimate Survival with Other Types of Progressive Fibrosis Interstitial Lung Disease: A Bayesian Framework
por: Langford, Bryony, et al.
Publicado: (2021)

Interstitial Lung Abnormalities and Aging Biomarkers: A Mediation
por: Oldham, Justin M.
Publicado: (2021)

Toward Early Detection of Idiopathic Pulmonary Fibrosis
por: Schupp, Jonas Christian, et al.
Publicado: (2019)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
por: Amati, Francesco, et al.
Publicado: (2022)

Autophagy in Idiopathic Pulmonary Fibrosis: Predisposition of the Aging Lung to Fibrosis?
por: Zmijewski, Jaroslaw W., et al.
Publicado: (2022)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?
por: Sgalla, Giacomo, et al.
Publicado: (2020)

Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Step Forward
por: Vancheri, Carlo, et al.
Publicado: (2022)

The 2018 Diagnosis of Idiopathic Pulmonary Fibrosis Guidelines: Surgical Lung Biopsy for Radiological Pattern of Probable Usual Interstitial Pneumonia Is Not Mandatory
por: Raghu, Ganesh, et al.
Publicado: (2019)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis Biomarker
por: Spagnolo, Paolo, et al.
Publicado: (2022)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Interstitial Lung Abnormalities: An Evolving Entity
por: Tomassetti, Sara, et al.
Publicado: (2022)

Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases
por: Pulito-Cueto, Verónica, et al.
Publicado: (2023)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

Stepping Stones
por: Chatterjee, Manas
Publicado: (2021)

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease
por: Cabrera Cesar, Eva, et al.
Publicado: (2021)

Interstitial lung abnormalities: do symptoms matter?
por: Patel, Avignat S.
Publicado: (2023)

Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019)

Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease
por: Zhang, David, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis and Lung Cancer: Finding Similarities within Differences
por: Reyfman, Paul A., et al.
Publicado: (2019)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Subclinical Interstitial Lung Abnormalities: Lumping and Splitting Revisited
por: Walsh, Simon L. F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lv5mvcgggr8bnfelt8bbd3g8dm